Animals in drug discovery and development

We work closely with over 40 pharmaceutical and biotechnology companies, contract research organisations and regulatory agencies from the UK, elsewhere in Europe, the USA and Asia to foster a cross-company approach to applying the 3Rs across the drug discovery and development pipeline.

We have focused our activities on identifying new 3Rs opportunities through our role as an honest broker for data sharing and our open innovation programme CRACK IT. Through these we have influenced company practice and regulatory guidelines and highlighted how the 3Rs can be applied without compromising the drug development process, regulatory requirements or human safety. 

Ending the requirement for conventional single dose acute toxicity testing prior to first-in-human studies.
Recommendations for maximum body weight loss limits for the rat, dog and non-human primates.
An independent and comprehensive review that will identify opportunities to incorporate non-animal testing approaches.
Replacing and reducing animal use for pharmacokinetic analysis of hepatically and renally cleared compounds
Avoiding the use of non-human primates.
Guidance on microsampling
Reducing the use of non-human primates in the development of biotherapeutics
Strategies to minimise the use of recovery animals
An ABPI-funded project reviewing whether the standard protocol for using two species can be modified.
Our office-led programme which aims to increase the utility of mechanistic approaches in safety assessment
Information and news on the development and application of pathways-based approaches
Guidance on best practice and recommendations for telemetry recordings from socially-housed non-rodents.
Bringing together experts in the fields of exposure science, efficacy and toxicology to increase the uptake of non-animal approaches
Additional information, resources and references